中国专家自主研发肺癌治疗三代靶向新药获批上市 - 2020年04月20日

The nation’s first self-developed targeted drug for terminal lung cancer patients who have developed a resistance to drugs has been approved by the national authority, experts from Shanghai Chest Hospital said on Friday.
Almonertinib is the world’s second such drug. Previously, there was only one imported medicine for such patients.
Dr Lu Shun, who led clinical trials, said the medicine had shown positive effects for many terminal lung cancer patients.